Arctic Bioscience - Investor Presentation 2022

Arctic Bioscience - Presentation at ABG Sundal Collier Life Science Summit

Arctic Bioscience is pleased to announce that CEO Christer L. Valderhaug and

Medical Director Runhild Gammelsæter will be presenting at the ABG Sundal

Collier Life Science Summit taking place on Thursday 19 May at 11:30 CET.

For further information, please contact:

Christer L. Valderhaug

CEO of Arctic Bioscience AS

Mobile: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

nutraceutical and pharmaceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel investigational drug candidate based

on herring roe. HRO350 is being developed for treatment of patients with mild-to

-moderate psoriasis. This is a large patient group in need of new effective

medicines with beneficial safety profile.

Herring roe contains lipids that are essential in maintaining cell membranes and

omega -3 fatty acids that contribute to the normal functioning of brain, heart,

and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk

ingredients as well as finished goods under the ROMEGA® brand. The strategy is

to switch sales from bulk to finished goods and focus markets are USA and China.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.

AI assistant